Table 2.
Design and characteristics of trials included in the systematic review and metaanalysis.
| Author (trial) | Year | Number of patients | Dosage of bisphosphonate | Combination therapy | Duration | Median follow up (months) | Intervention | Jadad score |
|---|---|---|---|---|---|---|---|---|
| Lombart et al. (E-ZO FAST) | 2009 | 527 | 4 mg IV every 6 months | 2.5 mg letrozole daily | 5 years | 36 | Immediate ZOL 4 mg every 6 months, delayed ZOL 4 mg every 6 months | 3 |
| Bundred et al. (ZO FAST) [17] | 2008 | 1065 | 4 mg IV every 6 months | 2.5 mg letrozole daily | 5 years | 48 | Immediate ZOL 4 mg every 6 months, delayed ZOL 4 mg every 6 months | 4 |
| Brufsky et al. (Z FAST) [16] | 2007 | 602 | 4 mg IV every 6 months | 2.5 mg letrozole daily | 5 years | 54 | Immediate ZOL 4 mg every 6 months, delayed ZOL 4 mg every 6 months | 4 |
| Van Poznak et al. (SABRE trial) [18] | 2010 | 234 | Residronate 35 mg per week | 1 mg Anastrozole daily | 2 years | 24 | Anastrozole + residronate, anastrozole + placebo |
4 |
| Markopoulos et al. (ARBI trial) [20] | 2010 | 213 | Residronate 35 mg per week | 1 mg Anastrozole daily | 3 years | 36 | Anastrozole + residronate, anastrozole + placebo | 3 |
| Lester et al. (ARIBON trial) [19] | 2008 | 131 | Ibandronate 150 mg every 28 day | 1 mg Anastrozole daily | 2 years | 24 | Anastrazole + ibandronate, anastrozole + placebo |
3 |